PA treatment led to reduction of DGAT, ACS, FAS, HMGCR, PPARγ, and C/EBPα mRNA levels (Figure 3A–F), whereas AMPK, SREBP-1c, FAS, ACC, PPARγ, FABP4, and C/EBPα protein levels were enhanced in NAFLD mice (Figure 3G–N). The gene discussed is FABP4; the disease is metabolic dysfunction-associated steatotic liver disease.